Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

CG Oncology (CGON) Shares Outstanding (2023 - 2025)

CG Oncology's Shares Outstanding history spans 3 years, with the latest figure at $80.7 million for Q4 2025.

  • For Q4 2025, Shares Outstanding rose 5.95% year-over-year to $80.7 million; the TTM value through Dec 2025 reached $80.7 million, up 5.95%, while the annual FY2025 figure was $80.7 million, 5.95% up from the prior year.
  • Shares Outstanding reached $80.7 million in Q4 2025 per CGON's latest filing, up from $78.3 million in the prior quarter.
  • In the past five years, Shares Outstanding ranged from a high of $80.7 million in Q4 2025 to a low of $3.9 million in Q1 2023.
  • Average Shares Outstanding over 3 years is $50.5 million, with a median of $67.1 million recorded in 2024.
  • Peak YoY movement for Shares Outstanding: soared 1627.96% in 2024, then rose 5.95% in 2025.
  • A 3-year view of Shares Outstanding shows it stood at $5.2 million in 2023, then soared by 1358.27% to $76.2 million in 2024, then rose by 5.95% to $80.7 million in 2025.
  • Per Business Quant, the three most recent readings for CGON's Shares Outstanding are $80.7 million (Q4 2025), $78.3 million (Q3 2025), and $76.2 million (Q2 2025).